Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Cardiovasc Med. 2003 Jul;13(5):169-75.

VEGF-A(164/165) and PlGF: roles in angiogenesis and arteriogenesis.

Author information

1
Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.

Abstract

Angiogenic cytokines such as vascular endothelial growth factor-A(164/165) (VEGF-A(164/165)) and placenta growth factor (PlGF) are being considered for therapeutic relief of coronary heart disease and other forms of tissue ischemia caused by atherosclerosis. Before proceeding further with clinical testing, it is important to determine what types of new blood vessels these cytokines actually induce and whether they could provide a useful new blood supply to ischemic tissues. In mice, VEGF-A(164/165) induced a transient angiogenic response (mother vessels, glomeruloid bodies, daughter capillaries), and stable arteriovenous malformations, arteriogenesis, and lymphangiogenesis; whereas PlGF only induced the formation of large, stable blood vessels. The large, long-lasting blood vessels induced by VEGF-A(164/165) and PlGF could provide an improved blood supply if positioned proximal to ischemic tissue, but VEGF-A(164/165)'s angiogenic response--which is short lived and accompanied by vascular hyperpermeability, edema, and fibrosis--would seem to offer little therapeutic benefit.

PMID:
12837578
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center